期刊文献+

伊马替尼疗效与晚期胃肠间质瘤临床病理特征分析 被引量:1

Analysis of the curative effect of Imatinib and clinicopathological features in advanced gastrointestinal stromal tumor
下载PDF
导出
摘要 目的探讨晚期胃肠间质瘤(GIST)临床病理特征对伊马替尼疗效的影响。方法回顾性分析74例晚期GIST患者的临床病理资料,并比较不同因素对伊马替尼疗效的影响。结果全组病例有效率(RR)为87.8%。性别、年龄、肿瘤原发部位与伊马替尼疗效无关(P>0.05)。单因素分析显示:危险度、转移灶手术情况、转移病灶与伊马替尼疗效有关(P<0.05)。多因素分析显示:转移灶手术情况、转移病灶是伊马替尼疗效的独立影响因素。逻辑回归分析显示:肝脏与多脏器转移,腹盆腔与多脏器转移的伊马替尼疗效差异有统计学意义(P<0.05)。结论危险度、转移灶手术情况、转移病灶是GIST伊马替尼疗效的影响因素,其中转移灶手术情况、转移病灶是伊马替尼疗效的独立影响因素;腹盆腔转移、肝脏转移、多脏器转移的伊马替尼疗效依次降低。 Objective To explore the effect of clinicopathological features on the curative effect of Imatinib in advaced gastrointestinal stromal tumor ( GIST) . Methods Retrospectively analyzed the clinicopathological data of 74 diagonosed patients with advanced GIST by histopathology and immunohistochemistry between September 2007 and July 2012 in The First Affiliated Hospital of Anhui Medical University. The impact factors of the curative effect of Imatinib were evaluated. Results The response rate of the curative effect of Imatinib in all patients was 87. 8%. The statistical analysis showed that there was no correlation between the curative effect of Imatinib and gender,age, tumor primary site(P〉0. 05). The univariate analysis revealed that risk,dissection of primary tumor,metastatic lesion are related to the curative effect of Imatinib ( P〈0 . 05 ) . The multivariate analysis revealed that dissection of primary tumor and metastatic lesion are independent factors impacting the curative effect of Imatinib. The Logistic regression analysis showed that there were significant differences between multiple organic metastasis and hepatic metastasis as well as between multiple organic metastasis and abdominal and pelvic metastasis ( P〈0 . 05 ) . Conclusion Risk, dissection of primary tumor, metastatic lesion are the impact factors of the curative effect of Imatinib. And dissection of primary tumor and metastatic lesion are independent factors impacting the curative effect of Imatinib. The curative effect of Imatinib in different metastatic lesion of abdominal and pelvic metastasis, hepatic metastasis and multiple organic metastasis are decreased in turn.
出处 《安徽医科大学学报》 CAS 北大核心 2014年第7期977-980,共4页 Acta Universitatis Medicinalis Anhui
基金 安徽省科技计划项目(编号:11070403056)
关键词 伊马替尼 胃肠间质瘤 单因素分析 多因素分析 Imatinib GIST univariate analysis multivariate analysis
  • 相关文献

参考文献12

  • 1Hirota S ,Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors [ J ]. Science, 1998,279(5350) :577 -80.
  • 2Heinrich M C, Corless C L, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors [ J ]. Science, 2003, 299(5607) :708 - 10.
  • 3中国胃肠间质瘤诊断治疗专家共识(2011年版)[J].中华胃肠外科杂志,2012,15(3):301-307. 被引量:117
  • 4Choi H. Response evaluation of gastrointestinal stromal tumors [ J ]. Oncologist,2008,13 ( 2 ) :4 - 7.
  • 5Bucher P,ViUiger P,Egger J F,et al. Management of gastrointesti- nal stromal turnouts:from diagnosis to treatment [ J ]. Swiss Med Wkly ,2004,134( 11 ) : 145 - 53.
  • 6鞠放,汪青,薛春燕,石静,王雅杰.甲磺酸伊马替尼治疗36例晚期胃肠道间质瘤的疗效分析[J].现代生物医学进展,2010,10(22):4258-4260. 被引量:6
  • 7Blanke C D,Demetri G D,von Mehren M,et al. Long-term results from a randomized phase II trim of standard-versus higher-dose Gleevee mesylate for patients with unreseetable ormetastatie gastro- intestinal Stromal Tumors expressing KIT[ J ]. J Clin Onco1,2008, 26(4) :620 - 5.
  • 8Joensuu H. Risk stratification of patients diagnosed with gastroin- testinal stromal tumor[ J ]. Hum Patho1,2008,39 ( 10 ) : 1411 - 9.
  • 9Li J, Gong F J, Shen L, et al. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor [ J ]. Euro J Sur Oncol,2011,37(4) :319 -24.
  • 10Heinrich M D, Corless C L. Gastric G! stromal tumors (GISTs) : the role of surgery in the era of targeted therapy [ J ]. J Surg Oncol, 2005,90 (3) : 195 - 207.

二级参考文献61

  • 1贺慧颖,方伟岗,钟镐镐,李燕,郑杰,杜娟,衡万杰,吴秉铨.165例胃肠道间质瘤中c-kit和PDGFRA基因突变的检测和临床诊断意义[J].中华病理学杂志,2006,35(5):262-266. 被引量:73
  • 2Blay JY, Le CA, Ray CI, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treat- ment beyond 1 year: the French Sarcoma Group [J]. J Clin Oncol, 2007, 25(9): 1107-1113.
  • 3Abdulkader I, Cameselle T J, Forteza J. Pathological changes related to Imatinib treatment in a patient with a metastatic gastrointestinal stromal tumour[J]. Histopathology, 2005, 46(4): 470-472.
  • 4Zhu J, Yang Y, Zhou L, et al. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome [J]. BMC Cancer, 2010, 10:199.
  • 5Ali S, All S. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST)[J]. Gene, 2007, 401(1-2): 38-45.
  • 6Parfitt JR, Streutker C J, Riddell RH, et al. Gastrointestinal stromal tumors: a contemporary review [J]. Pathol Res Pract, 2006, 202(12): 837-847.
  • 7Cirocchi R, Farinella E, La Mura F, et al. Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: a systematic review [J]. Tumori, 2010, 96(3): 392-399.
  • 8Goettsch WG, Bos SD, Breekveldt PN, et al. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study[J]. Eur J Cancer, 2005, 41(18): 2868-2872.
  • 9Gupta P, Tewari M, Shukla HS. Gastrointestinal stromal tumor [J]. Surg Oncol, 2008, 17(2): 129-138.
  • 10DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival [J]. Ann Surg, 2000, 231(1): 51-58.

共引文献121

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部